Literature DB >> 23690418

Ipilimumab-induced hepatitis C viral suppression.

Steven Minter1, Ira Willner, Keisuke Shirai.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23690418     DOI： 10.1200/JCO.2012.46.5831

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?

Authors:  Daniel E Speiser; Daniel T Utzschneider; Susanne G Oberle; Christian Münz; Pedro Romero; Dietmar Zehn
Journal:  Nat Rev Immunol       Date:  2014-09-26       Impact factor: 53.106

2.  Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.

Authors:  Katharina Lankes; Gheorghe Hundorfean; Thomas Harrer; Ansgar J Pommer; Abbas Agaimy; Irena Angelovska; Azadeh Tajmir-Riahi; Jonas Göhl; Gerold Schuler; Markus F Neurath; Werner Hohenberger; Lucie Heinzerling
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

3.  Predictors of immunotherapy-induced immune-related adverse events.

Authors:  A Kartolo; J Sattar; V Sahai; T Baetz; J M Lakoff
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 4.  Hepatitis C virus reactivation in cancer patients in the era of targeted therapies.

Authors:  Ozan Yazici; Mehmet Ali Nahit Sendur; Sercan Aksoy
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 5.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

6.  Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.

Authors:  Sowmya Ravi; Kristen Spencer; Mary Ruisi; Nageatte Ibrahim; Jason J Luke; John A Thompson; Keisuke Shirai; David Lawson; Heddy Bartell; Ragini Kudchadkar; Ngoc Thi Gunter; Janice M Mehnert; Evan J Lipson
Journal:  J Immunother Cancer       Date:  2014-10-14       Impact factor: 13.751

Review 7.  Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.

Authors:  Isobel S Okoye; Michael Houghton; Lorne Tyrrell; Khaled Barakat; Shokrollah Elahi
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

8.  Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Authors:  Dan Pu; Liyuan Yin; Yuwen Zhou; Wen Li; Lin Huang; Liang Cai; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 9.  Immunotherapies for COVID-19: lessons learned from sepsis.

Authors:  Kenneth E Remy; Scott C Brakenridge; Bruno Francois; Thomas Daix; Clifford S Deutschman; Guillaume Monneret; Robin Jeannet; Pierre-Francois Laterre; Richard S Hotchkiss; Lyle L Moldawer
Journal:  Lancet Respir Med       Date:  2020-04-28       Impact factor: 30.700

10.  Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike.

Authors:  Eizo Watanabe; Lukose K Thampy; Richard S Hotchkiss
Journal:  Acute Med Surg       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.